Persistence of Immune Response After Vaccination With MCC

Prevention of Meningococcal Infection Clinical Trial

Official title:
A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign

Status Completed

Clinical Trial Summary

Persistence of Immune response after vaccination with MCC

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Meningococcal Infections
Prevention of Meningococcal Infection

Clinical Trial Details

NCT number	NCT00310687
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	October 2004
Completion date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00310674` - Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age	Phase 3
Completed	`NCT00311415` - Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children	Phase 3
Completed	`NCT00310700` - Kinetics of B Cell Response in Infants Menjugate Vaccination	Phase 4
Completed	`NCT00316654` - Persistence of Antibody Response to N. Meningitidis Group C in Children	Phase 4
Completed	`NCT00310713` - Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine	Phase 4